GAVISCON PEPPERMINT LIQUID RELIEF

For oral administration. Adults and children over 12 years: 10-20ml after meals and at bedtime.

Children under 12 years:

Should be given only on medical advice.

Elderly:

No dosage modification is required in this age group.

Hepatic Impairment:

No dose modification necessary. 4).

Adverse reactions have been ranked under headings of frequency using the following convention: very common (1/10), common (1/100 and <1/10), uncommon (1/1000 and <1/100), rare (1/10,000 and <1/1000), very rare (< 1/10,000) and not known (cannot be estimated from the available data).

System Organ Class Frequency Adverse Event Immune System Disorders Very rare Anaphylactic and anaphylactoid reactions. Hypersensitivity reactions such as urticaria. Respiratory, Thoracic and Mediastinal Disorders Very rare Respiratory effects such as bronchospasm.

Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

If symptoms do not improve after 7 days, the clinical situation should be reviewed. 26 % of the WHO recommended maximum daily intake for sodium. The maximum daily dose of this product is equivalent to 57 % of the WHO recommended maximum daily intake for sodium.

This product is considered high in sodium. g. in some cases of congestive heart failure and renal impairment). 6 mmol) of calcium carbonate. Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi.

Contains methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate (E216) which may cause allergic reactions (possibly delayed).

4).